Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy

Journal of Controlled Release

Volumn 166, Issue 3, 2013, Pages 203-210

  Xu, Keming ^a   Lee, Fan ^a   Gao, Shu Jun ^a   Chung, Joo Eun ^a   Yano, Hirohisa ^a,b   Kurisawa, Motoichi ^a  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hyaluronic acid; Hydrogel; Injectable; Interferon; Protein delivery

Indexed keywords

ANGIOGENESIS; ANTI-TUMOR EFFICACY; APOPTOTIC; CASPASE-3/7; CELL DENSITY; HORSERADISH PEROXIDASE; HYDROGEL TREATMENTS; IN-VITRO; INDUCED APOPTOSIS; INJECTABLE; INJECTABLE HYDROGELS; LIVER CANCER CELLS; LIVER CANCERS; OXIDATIVE COUPLINGS; POST INJECTION; PROLIFERATING CELLS; PROTEIN DELIVERY; RHEOLOGICAL PROPERTY; TUMOR GROWTH; TUMOR REGRESSION; TUMOR TISSUES; VARYING STIFFNESS;

AMINES; ANTIBIOTICS; CELL PROLIFERATION; GLYCOPROTEINS; HISTOLOGY; HYALURONIC ACID; HYDROGEN PEROXIDE; INTERFERONS; MAMMALS; ONCOLOGY; ORGANIC ACIDS; STIFFNESS; TUMORS;

HYDROGELS;

ALPHA2A INTERFERON; CASPASE 3; CASPASE 7; HORSERADISH PEROXIDASE; HYALURONIC ACID; HYALURONIC ACID TYRAMINE; HYDROGEN PEROXIDE; TYRAMINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL DENSITY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DESIGN; DRUG EFFECT; DRUG RELEASE; FEMALE; HUMAN; HUMAN CELL; HYDROGEL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; MOUSE; NONHUMAN; OXIDATIVE COUPLING; PRIORITY JOURNAL; RIGIDITY; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG CARRIERS; FEMALE; HUMANS; HYALURONIC ACID; HYDROGELS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SOLUBILITY; TYRAMINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873421323     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.01.008     Document Type: Article

References (31)

1. G. Walsh Biopharmaceutical benchmarks 2010 Nat. Biotechnol. 28 2010 917 924
2. B. Leader, Q.J. Baca, and D.E. Golan Protein therapeutics: a summary and pharmacological classification Nat. Rev. Drug Discov. 7 2008 21 39
3. A.C. Chan, and P.J. Carter Therapeutic antibodies for autoimmunity and inflammation Nat. Rev. Immunol. 10 2010 301 316
4. L.M. Weiner, R. Surana, and S. Wang Monoclonal antibodies: versatile platforms for cancer immunotherapy Nat. Rev. Immunol. 10 2010 317 327
5. N. Lonberg Fully human antibodies from transgenic mouse and phage display platforms Curr. Opin. Immunol. 20 2008 450 459
6. R.E. Kontermann Strategies for extended serum half-life of protein therapeutics Curr. Opin. Biotechnol. 22 2011 868 876
7. W.H. Vogel Infusion reactions: diagnosis, assessment, and management Clin. J. Oncol. Nurs. 14 2010 E10 E21
8. A.S. Hoffman Hydrogels for biomedical applications Adv. Drug Deliv. Rev. 54 2002 3 12
9. L.S. Wang, J.E. Chung, P.P.Y. Chan, and M. Kurisawa Injectable biodegradable hydrogels with tunable mechanical properties for the stimulation of neurogenesic differentiation of human mesenchymal stem cells in 3D culture Biomaterials 31 2010 1148 1157
10. W.S. Toh, T.C. Lim, M. Kurisawa, and M. Spector Modulation of mesenchymal stem cell chondrogenesis in a tunable hyaluronic acid hydrogel microenvironment Biomaterials 33 2012 3835 3845
11. M. Kurisawa, J.E. Chung, Y.Y. Yang, S.J. Gao, and H. Uyama Injectable biodegradable hydrogels composed of hyaluronic acid-tyramine conjugates for drug delivery and tissue engineering Chem. Commun. 14 2005 4312 4314
12. M. Kurisawa, F. Lee, L.S. Wang, and J.E. Chung Injectable enzymatically crosslinked hydrogel system with independent tuning of mechanical strength and gelation rate for drug delivery and tissue engineering J. Mater. Chem. 20 2010 5371 5375
13. F. Lee, J.E. Chung, and M. Kurisawa An injectable enzymatically crosslinked hyaluronic acid-tyramine hydrogel system with independent tuning of mechanical strength and gelation rate Soft Matter 4 2008 880 887
14. F. Lee, J.E. Chung, and M. Kurisawa An injectable hyaluronic acid-tyramine hydrogel system for protein delivery J. Control. Release 134 2009 186 193
15. X.Z. Shu, Y.C. Liu, F.S. Palumbo, Y. Lu, and G.D. Prestwich In situ crosslinkable hyaluronan hydrogels for tissue engineering Biomaterials 25 2004 1339 1348
16. S. Cai, Y. Liu, X. Zheng Shu, and G.D. Prestwich Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor Biomaterials 26 2005 6054 6067
17. C.M. Nimmo, S.C. Owen, and M.S. Shoichet Diels-Alder click cross-linked hyaluronic acid hydrogels for tissue engineering Biomacromolecules 12 2011 824 830
18. J.H. Hoofnagle, K.D. Mullen, D.B. Jones, V. Rustgi, A. Dibisceglie, M. Peters, J.G. Waggoner, Y. Park, and E.A. Jones Treatment of chronic non-A, non-B Hepatitis with recombinant human alpha-interferon - a preliminary report N. Engl. J. Med. 315 1986 1575 1578
19. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden, and A.S. Perelson Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107
20. H. Yano, A. Iemura, M. Haramaki, S. Ogasawara, A. Takayama, J. Akiba, and M. Kojiro Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines Hepatology 29 1999 1708 1717
21. T. Hisaka, H. Yano, S. Ogasawara, S. Momosaki, N. Nishida, Y. Takemoto, S. Kojiro, Y. Katafuchi, and M. Kojiro Interferon-alpha Con1 suppresses proliferation of liver cancer cell lines in vitro and in vivo J. Hepatol. 41 2004 782 789
22. H. Yano, A. Iemura, K. Fukuda, A. Mizoguchi, M. Haramaki, and M. Kojiro Establishment of 2 distint human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells Hepatology 18 1993 320 327
23. J.M. Vrolijk, A. Kaul, B.E. Hansen, V. Lohmann, B.L. Haagmans, S.W. Schalm, and R. Bartenschlager A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C J. Virol. Methods 110 2003 201 209
24. T. Pietschmann, M. Zayas, P. Meuleman, G. Long, N. Appel, G. Koutsoudakis, S. Kallis, G. Leroux-Roels, V. Lohmann, and R. Bartenschlager Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations PLoS Pathog. 5 2009 14
25. J.B. Leach, K.A. Bivens, C.W. Patrick, and C.E. Schmidt Photocrosslinked hyaluronic acid hydrogels: natural, biodegradable tissue engineering scaffolds Biotechnol. Bioeng. 82 2003 578 589
26. C. Dhalluin, A. Ross, L.A. Leuthold, S. Foser, B. Gsell, F. Muller, and H. Senn Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers Bioconjug. Chem. 16 2005 504 517
27. S. Kamada, U. Kikkawa, Y. Tsujimoto, and T. Hunter Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein(s) J. Biol. Chem. 280 2005 857 860
28. J. Bullwinkel, B. Baron-Luhr, A. Ludemann, C. Wohlenberg, J. Gerdes, and T. Scholzen Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells J. Cell. Physiol. 206 2006 624 635
29. N. Ferrara, and R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 2005 967 974
30. D. Ribatti, A. Vacca, B. Nico, D. Sansonno, and F. Dammacco Angiogenesis and anti-angiogenesis in hepatocellular carcinoma Cancer Treat. Rev. 32 2006 437 444
31. M.-C. Bettencourt, J.J. Bauer, I.A. Sesterhenn, R.R. Connelly, and J.W. Moul CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy J. Urol. 160 1998 459 465